Schizoaffective Disorder Clinical Trial
Official title:
Do Patients Taking Aripiprazole Learn More in Vocational Skills Training Than Patients Taking Olanzapine?
STUDY PURPOSE: To study whether patients who have schizophrenia or schizoaffective disorder and are randomly assigned to switch to aripiprazole prior to participation in a brief vocational skills training (VST) will have improved cognitive functioning and learn more in VST than those randomly assigned to stay on olanzapine. There is evidence that VST is important in improving role functioning for schizophrenia patients, however, cognitive impairments limit the ability of some patients to benefit from skills training approaches. Patients switched from olanzapine to aripiprazole improve in terms of verbal learning and verbal learning has been shown to be a strong predictor of community outcome. It is unclear whether the cognitive benefits of switching to aripiprazole extend to improve learning of vocational skills.
Many schizophrenia outpatients have cognitive deficits and poor vocational functioning. There is evidence from randomized controlled trials that vocational skills training is important in improving vocational role functioning for schizophrenia patients. However, it has become clear that cognitive impairments limit the ability of patients to benefit from skills training approaches. Recent research demonstrates that patients switched from olanzapine to aripiprazole improve in terms of verbal learning. Verbal learning has been found to be a strong predictor of multiple domains of community outcome. It is unclear whether the cognitive benefits of switching to aripiprazole extend to improve learning of vocational skills. This study examines whether aripiprazole can improve the ability to benefit from expensive rehabilitation programs focused on skill-building. Specifically, the study examines whether patients who switch from olanzapine to aripiprazole learn more and benefit more from a brief vocational skills program than patients who remain on olanzapine. Specific aims are as follows: (1) we hypothesize that patients on aripiprazole will demonstrate better scores on tests of cognitive functioning following twelve weeks of medication treatment than patients on olanzapine and (2) we hypothesize that patients on aripiprazole will have significantly higher scores on vocational performance following a brief (2-day) vocational training and assessment session than those on olanzapine. Furthermore, we hypothesize that these gains will be maintained following one week of non-exposure to the trained vocational tasks. ;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT01878513 -
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis
|
N/A | |
Recruiting |
NCT05030272 -
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
|
N/A | |
Recruiting |
NCT04298450 -
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
|
N/A | |
Not yet recruiting |
NCT04551027 -
Assessing the Effect of Compensatory Cognitive Intervention Among People With Severe Mental Illness
|
N/A | |
Terminated |
NCT02796144 -
MEtformin and Lorcaserin for WeighT Loss in Schizophrenia
|
Phase 4 | |
Completed |
NCT02901587 -
Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT02160249 -
RISE (Rehabilitation Intervention for People With Schizophrenia in Ethiopia)
|
N/A | |
Recruiting |
NCT02986490 -
Magnesium Variations and Cardiometabolic Risk in Patients With Antipsychotic Drugs
|
N/A | |
Completed |
NCT02091388 -
Bioavailability of LY03004 and Risperdal® Consta®
|
Phase 1 | |
Completed |
NCT02417142 -
Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia
|
Phase 4 | |
Terminated |
NCT02234752 -
Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia
|
Phase 2 | |
Terminated |
NCT02149823 -
Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
|
Phase 1 | |
Completed |
NCT01945333 -
Personalized and Scalable Cognitive Remediation Approaches
|
N/A | |
Completed |
NCT01975584 -
Neuroendocrine and Immune Response to Stress in Schizophrenia
|
N/A | |
Completed |
NCT01992393 -
Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME)
|
N/A | |
Completed |
NCT01683539 -
Understanding How Cognitive Remediation Works
|
N/A | |
Completed |
NCT01658150 -
Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder
|
N/A | |
Completed |
NCT01292577 -
Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia
|
Phase 1/Phase 2 |